Neurodevelopmental Assessment of Infants With Cystic Fibrosis

Hacettepe University

Status: Completed

Conditions: Neurodevelopmental Disorders; Cystic Fibrosis

Treatments: Other: Neurodevelopmental assessments

Study type: Observational

Funder types: Other

Identifiers

NCT03577756

earlyrehabcysticfibrosis

Details and patient eligibility

About

Infants included in the study will be divided into two groups as healthy infants and cystic fibrosis infants . Demographic, natal and postnatal information of the infants will be available from patient files. 12 months infants with cystic fibrosis and healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Gross Motor Function Measure. The assessment outcomes of healthy and cystic fibrosis infants will be compared.

Enrollment: 24 patients

Sex: All

Ages: 24 to 36 months old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• having diagnosis of cystic fibrosis
• to be postterm24-36 months old

Exclusion criteria

• Having congenital anomalies,
• Having an acute infection,
• Risk of high or low neurological impairment due to perinatal stroke, perinatal asphyxia, intra / peri-ventricular hemorrhage (IVH / PVL), bronchopulmonary dysplasia,
• The baby's family not reluctant to involved in study.

Trial design

24 participants in 2 patient groups

Infants with cystic fibrosis

Description:

Twelve months infants with cystic fibrosis will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.

Treatment:

Other: Neurodevelopmental assessments

Healthy infants

Description:

Twelve months healthy infants will be assessed by the Bayley-III Baby and Child Development Assessment Scale (Bayley III) and the Rough Motor Function Measure.

Treatment:

Other: Neurodevelopmental assessments